您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > JWH 398 N-(4-hydroxypentyl)metabolite
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
JWH 398 N-(4-hydroxypentyl)metabolite
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
JWH 398 N-(4-hydroxypentyl)metabolite图片
CAS NO:1537889-06-7
规格:98%
分子量:391.9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
JWH 398 is a synthetic cannabinoid (CB) that activates both central CB1 and peripheral CB2 receptors (Ki = 2.3 and 2.8 nM, respectively).
CAS:1537889-06-7
分子式:C24H22ClNO2
分子量:391.9
纯度:98%
存储:Store at -20°C

Background:

JWH 398 is a synthetic cannabinoid (CB) that activates both central CB1 and peripheral CB2 receptors (Ki = 2.3 and 2.8 nM, respectively).[1] It has been reported to be an adulterant of herbal products.[2],[3] JWH 398 N-(4-hydroxypentyl) metabolite is an expected phase I metabolite of JWH 398, detectable in serum and urine. While similar hydroxylated phase I metabolites of synthetic CBs retain activity, the physiological properties of this compound have yet to be determined.[4],[5] This product is intended for research and forensic applications.


Reference:
[1]. Huffman, J.W. Cannabimimetic indoles, pyrroles, and indenes: Structure-activity relationships and receptor interactions. The cannabinoid receptors 49-95 (2009).
[2]. Kikura-Hanajiri, R., Uchiyama, N., and Goda, Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med. (Tokyo) 13(3), 109-115 (2011).
[3]. Dresen, S., Ferreirós, N., Pütz, M., et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. Journal of Mass Spectrometry 45(10), 1186-1194 (2010).
[4]. Brents, L.K., Reichard, E.E., Zimmerman, M., et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6(7), 1-9 (2011).
[5]. Brents, L.K., Gallus-Zawala, A., Radominska-Pandya, A., et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retainintermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutralantagonist to partial agonist activity. Biochemical Pharmacology 83, 952-961 (2012).